Pfizer And BioNTech Claim COVID-19 Vaccine Success

Interim Analysis Finds Vaccine 90% Effective, EUA Filing Expected Late November

The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.

Pfizer
Pfizer and BioNTech have produced better than expected efficacy results - but will wait for safety data before filing later this month.

Pfizer and BioNTech have announced what the world has been waiting for – positive interim Phase III results for their mRNA-based COVID-19 vaccine, BNT162b2, suggesting that it is 90% effective in preventing infection.

While the full data have yet to be published in a peer-reviewed journal, the topline result is a huge step...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip